Daily single-tablet antiretroviral therapy has significantly improved HIV care, but maintaining strict adherence remains challenging for many people living with HIV. Less frequent dosing strategies may help reduce treatment burden while preserving viral suppression. The primary endpoint was maintenance of viral suppression at 48 weeks. Viral suppression (HIV-1 RNA below 50 copies/mL) was maintained in 93.4% of participants receiving ISL/LEN and 92.4% of those continuing daily B/F/TAF, demonstrating that the weekly regimen was noninferior to standard daily therapy. The researchers concluded that once-weekly oral islatravir–lenacapavir was noninferior to the standard once-daily bictegravir–emtricitabine–tenofovir alafenamide regimen in maintaining viral suppression among adults with virologically suppressed HIV-1.